Both low and high serum IGF-1 levels associate with increased risk of cardiovascular events in elderly men.

CONTEXT Most previous prospective studies suggest that low serum IGF-1 associates with increased risk of cardiovascular disease (CVD) events whereas other studies suggest that high serum IGF-1 associates with increased risk of CVD events. OBJECTIVE We tested the hypothesis that not only low, but also high serum IGF-1 levels associate with increased risk of CVD events in elderly men. SETTING AND DESIGN Serum IGF-1 levels were measured in 2901 elderly men (age 69-81 years) included in the Swedish cohort of the prospective, population-based Osteoporotic Fractures in Men Study (MrOS), Sweden cohort. Data for CVD events were obtained from national Swedish registers with no loss of followup. RESULTS During followup (median, 5.1 y) 589 participants experienced a CVD event. The association between serum IGF-1 and risk of CVD events was nonlinear, and restricted cubic spline Cox regression analysis revealed a U-shaped association between serum IGF-1 levels and CVD events (P < .01 for nonlinearity). Low as well as high serum IGF-1 (quintile 1 or 5 vs quintiles 2-4) significantly associated with increased risk for CVD events (hazard ratio [HR] = 1.25, 95% confidence interval, [CI], 1.02-1.54; and HR = 1.35, 95% CI 1.10-1.66, respectively). These associations remained after adjustment for prevalent CVD and multiple risk factors. High serum IGF-1 associated with increased risk of coronary heart disease (CHD) events but not with risk of cerebrovascular events. CONCLUSIONS Both low and high serum IGF-1 levels are risk markers for CVD events in elderly men. The association between high serum IGF-1 and CVD events is mainly driven by CHD events.

[1]  P. Lips,et al.  Serum IGF1, metabolic syndrome, and incident cardiovascular disease in older people: a population-based study. , 2013, European journal of endocrinology.

[2]  M. Petzold,et al.  Both low and high serum IGF-I levels associate with cancer mortality in older men. , 2012, The Journal of clinical endocrinology and metabolism.

[3]  D. Arveiler,et al.  Effects of insulin-like growth factor 1 in preventing acute coronary syndromes: the PRIME study. , 2011, Atherosclerosis.

[4]  M. Zwahlen,et al.  Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. , 2011, The Journal of clinical endocrinology and metabolism.

[5]  G. Hankey,et al.  Associations of IGF1 and IGFBPs 1 and 3 with all-cause and cardiovascular mortality in older men: the Health In Men Study. , 2011, European journal of endocrinology.

[6]  M. Rezai,et al.  Changes in arterial stiffness but not carotid intimal thickness in acromegaly. , 2011, The Journal of clinical endocrinology and metabolism.

[7]  P. Lips,et al.  The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study. , 2010, The Journal of clinical endocrinology and metabolism.

[8]  P. Stewart,et al.  Mortality in patients with pituitary disease. , 2010, Endocrine reviews.

[9]  K. Sjögren,et al.  The role of liver-derived insulin-like growth factor-I. , 2009, Endocrine reviews.

[10]  G. Brabant,et al.  Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. , 2009, The Journal of clinical endocrinology and metabolism.

[11]  G. Sesti,et al.  Reciprocal Association of Plasma IGF-1 and Interleukin-6 Levels With Cardiometabolic Risk Factors in Nondiabetic Subjects , 2008, Diabetes Care.

[12]  S. Lamberts,et al.  Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality. , 2008, The Journal of clinical endocrinology and metabolism.

[13]  L. Kuller,et al.  Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. , 2007, The Journal of clinical endocrinology and metabolism.

[14]  D. Leroith,et al.  The role of the IGF system in cancer growth and metastasis: overview and recent insights. , 2007, Endocrine reviews.

[15]  O. Johnell,et al.  Free Testosterone is an Independent Predictor of BMD and Prevalent Fractures in Elderly Men: MrOS Sweden , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  A. Tjønneland,et al.  Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. , 2005, The Journal of clinical endocrinology and metabolism.

[17]  S. Cummings,et al.  Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. , 2005, Contemporary clinical trials.

[18]  J. Svensson,et al.  Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. , 2004, The Journal of clinical endocrinology and metabolism.

[19]  P. Marzullo,et al.  Systemic complications of acromegaly: epidemiology, pathogenesis, and management. , 2004, Endocrine reviews.

[20]  Ralph D'Agostino,et al.  Serum Insulin-like Growth Factor I and Risk for Heart Failure in Elderly Individuals without a Previous Myocardial Infarction: The Framingham Heart Study , 2003, Annals of Internal Medicine.

[21]  R. Clayton.  Cardiovascular function in acromegaly. , 2003, Endocrine reviews.

[22]  T. Jørgensen,et al.  Heart Disease : A Population-Based Case-Control Study Low Serum Insulin-Like Growth Factor I Is Associated With Increased Risk of Ischemic , 2002 .

[23]  A. Hofman,et al.  A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. , 2001, Diabetes.

[24]  K. Wheatley,et al.  Association between premature mortality and hypopituitarism , 2001, The Lancet.

[25]  N. Rifai,et al.  Effects of Growth Hormone Administration on Inflammatory and Other Cardiovascular Risk Markers in Men with Growth Hormone Deficiency , 2000, Annals of Internal Medicine.

[26]  L. Råstam,et al.  Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers , 2000, European Journal of Epidemiology.

[27]  D. Leroith,et al.  Normal growth and development in the absence of hepatic insulin-like growth factor I. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Sjögren,et al.  Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Grobbee,et al.  Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[30]  S. Lamberts,et al.  The endocrinology of aging. , 1997, Science.

[31]  G. Brabant,et al.  Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. , 1996, The Journal of clinical investigation.

[32]  A. Cittadini,et al.  Growth hormone and the heart. , 1994, Endocrine reviews.

[33]  B. Bengtsson,et al.  Premature mortality due to cardiovascular disease in hypopituitarism , 1990, The Lancet.

[34]  R. Simon,et al.  Flexible regression models with cubic splines. , 1989, Statistics in medicine.

[35]  J. Jansson,et al.  Sexual dimorphism in the control of growth hormone secretion. , 1985, Endocrine reviews.

[36]  P. Hildebrandt,et al.  IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. , 2009, European journal of endocrinology.

[37]  E. Barrett-Connor,et al.  The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. , 2004, The Journal of clinical endocrinology and metabolism.